Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA7 | P43166 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169931 | 1.00 | TRPV1 (0.53) | TRPV1TRPV4CA12CA1CA2 | |
| SCHEMBL11910662 | 0.87 | CA12 (0.60) | TRPV1TRPV4CA12CA1CA2 | |
| SCHEMBL11997977 | 0.85 | TRPV1 (0.58) | TRPV1TRPV4CA12CA1CA2 | |
| SCHEMBL5690946 | 0.81 | TRPV1 (0.46) | TRPV1TRPV4CA12CA1CA2 | |
| SCHEMBL23408969 | 0.79 | PDPK1 (0.54) | TRPV1TRPV4CA12CA1CA2 | |
| SCHEMBL4792781 | 0.77 | TRPV1 (0.45) | TRPV1TRPV4CA12CA1CA2 | |
| SCHEMBL30049354 | 0.75 | CA12 (0.59) | TRPV1TRPV4CA12CA1CA2 | |
| SCHEMBL1441195 | 0.74 | CA1 (0.57) | CA1CA2LMNA | |
| SCHEMBL2073072 | 0.74 | CA1 (0.57) | CA1CA2LMNA | |
| SCHEMBL30751997 | 0.74 | CA1 (0.57) | CA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2012779-B1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2012779-B1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2011-02-17 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | UTS2R, VIPR1, VRK1 | TRPV1 6/4885TRPV4 15/4885CA12 4629/4885 |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | UTS2R, VIPR1, VRK1 | TRPV1 4/4885TRPV4 13/4885CA12 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.